返回 
加入收藏
帕利哌酮治疗精神分裂症的临床观察
x
请在关注微信后，向客服人员索取文件
| 篇名： | 帕利哌酮治疗精神分裂症的临床观察 |
| TITLE： | |
| 摘要： | 目的：观察帕利哌酮治疗精神分裂症（Sz）的临床疗效与安全性。方法：选取Sz患者120例，按随机数字表法分为对照组和观察组，各60例。对照组患者给予常规药物利培酮片第1周2～4 mg，第2周加至4～6 mg，bid，维持至疗程结束；观察组患者给予帕利哌酮缓释片起始剂量3 mg，根据病情可增加至6～12 mg，qd。两组患者均治疗12周。观察两组患者临床疗效及治疗前后阳性与阴性症状量表（PANSS）评分、生活质量量表（SQLS）评分及不良反应发生情况。结果：观察组患者总有效率为93.3％，显著高于对照组的80.0％，差异有统计学意义（P＜0.05）。治疗前，两组患者PANSS及各项评分比较，差异无统计学意义（P＞0.05），但治疗后均显著降低，且观察组低于对照组，差异有统计学意义（P＜0.05）。治疗前，两组患者SQLS及各项评分比较，差异无统计学意义（P＞0.05），但治疗后均显著升高，且观察组高于对照组，差异有统计学意义（P＜0.05）。两组患者不良反应发生率比较，差异无统计学意义（P＞0.05）。结论：帕利哌酮缓释片治疗Sz的疗效显著，安全性较好。 |
| ABSTRACT： | OBJECTIVE： To observe clinical efficacy and safety of paliperidone in the treatment of schizophrenia （Sz）. METHODS： 120 Sz patients were selected and randomly divided into control group and observation group， with 60 cases in each group. Control group was given conventional medicine Risperidone tablet 2-4 mg in the first week， increasing to 4-6 mg in the second week till the end of treatment course. Observation group was given Risperidone sustained-release tablet with initial dose of 3 mg， increasing to 6-12 mg according to disease condition， qd. Both group were treated for 12 weeks. Clinical efficacy of 2 groups were observed， and PANSS， SQLS and ADR were also observed before and after treatment. RESULTS： Total effective rate of observation group was 93.3％， which was significantly higher than 80.0％ of control group， with statistical significance （P＜0.05）. Before treatment， there was no statistical significance in PANSS and those scores between 2 groups （P＞0.05）， and those of 2 groups decreased significantly， the observation group was lower than the control group， with statistical significance （P＜0.05）. Before treatment， there was no statistical significance in SQLS and those score between 2 groups （P＞0.05）， and those of 2 groups increased significantly after treatment， the observation group was higher than the control group， with statistical significance （P＜0.05）. There was no statistical significance in the incidence of ADR between 2 groups （P＞0.05）. CONCLUSIONS： Paliperidone is effective and safe in the treatment of Sz. |
| 期刊： | 2016年第27卷第14期 |
| 作者： | 谭艳菊，廖勇，白荣，汪应瑞 |
| AUTHORS： | TAN Yanju，LIAO Yong，BAI Rong，WANG Yingrui |
| 关键字： | 帕利哌酮；精神分裂症；生活质量；疗效；安全性 |
| KEYWORDS： | Paliperidone； Schizophrenia； Life quality； Clinical efficacy； Safety |
| 阅读数： | 378 次 |
| 本月下载数： | 8 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
